Podoplanin-CLEC2活化血小板与肿瘤相关性的研究进展

doi:10.11904/j.issn.1002-3070.2021.02.014

摘要/Abstract

摘要： Podoplanin是在多种肿瘤细胞表面表达的跨膜唾液酸样糖蛋白,是血小板C型凝集素样受体2(C-type lectin-like receptor 2,CLEC2)的内源性配体。Podoplanin通过CLEC2,可诱导强大的血小板聚集,参与肿瘤进展及癌症相关血栓形成。基于这些发现,抗Podoplanin和CLEC2靶向药物有望成为治疗肿瘤的新疗法。本综述将深入讨论Podoplanin-CLEC2活化血小板在肿瘤发生发展中的作用,以及就如何开发Podoplanin-CLEC2作为治疗靶点的潜在研究展开讨论。

关键词: 血小板, C型凝集素样受体2, Podoplanin, 肿瘤, 血栓形成

Abstract: Podoplanin is a transmembrane sialate-like glycoprotein expressed on the surface of a variety of tumor cells.It is the endogenous ligand of platelet C-type lectin-like receptor(CLEC2).Podoplanin can induce powerful platelet aggregation through CLEC2,and participate in cancer-related thrombosis.Based on these findings,anti-podoplanin and anti-CLEC2 targeted drugs are expected to become new therapies for the treatment of tumors.This review will discuss deeply the role of podoplanin-CLEC2 activated platelets in tumorigenesis and development,and discuss how to develop podoplanin-CLEC2 as a therapeutic target.

Key words: Platelet;C-type lectin-like receptor 2;Podoplanin;Tumor;Thrombosis

中图分类号:

李铭铭, 岳晨曦, 张梦琳, 黄文娟, 王瑞涛. Podoplanin-CLEC2活化血小板与肿瘤相关性的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 174-178.

LI Mingming, YUE Chenxi, ZHANG Menglin, HUANG Wenjuan, WANG Ruitao. Research progress on the relationship between Podoplanin-CLEC2 activation of platelets and tumors[J]. Journal of Practical Oncology, 2021, 35(2): 174-178.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.02.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I2/174

参考文献

1 Hisada Y,Mackman N.Cancer-associated pathways and biomarkers of venous thrombosis[J].Blood,2017,130(13):1499-1506.
2 Mukai M,Oka T.Mechanism and management of cancer-associated thrombosis[J].J Cardiol,2018,72(2):89-93.
3 Ünlü B,Versteeg HH.Cancer-associated thrombosis:the search for the holy grail continues[J].Res Pract Thromb Haemost,2018,2(4):622-629.
4 Li N,Yu Z,Zhang X,et al.Elevated mean platelet volume predicts poor prognosis in colorectal cancer[J].Sci Rep,2017,7(1):10261.
5 Yun ZY,Zhang X,Liu YS,et al.Lower mean platelet volume predicts poor prognosis in renal cell carcinoma[J].Sci Rep,2017,7(1):6700.
6 Takemoto A,Miyata K,Fujita N.Platelet-activating factor podoplanin:from discovery to drug development[J].Cancer Metastasis Rev,2017,36(2):225-234.
7 Miyata K,Takemoto A,Okumura S,et al.Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation[J].Sci Rep,2017,7(1):4059.
8 Nagae M,Morita-Matsumoto K,Kato M,et al.A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin[J].Structure,2014,22(12):1711-1721.
9 Tone K,Stappers MHT,Willment JA,et al.C-type lectin receptors of the Dectin-1 cluster:Physiological roles and involvement in disease[J].Eur J Immunol,2019,49(12):2127-2133.
10 Bieniasz-Krzywiec P,Martín-Pérez R,Ehling M,et al.Podoplanin-expressing macrophages promote lymphangiogenesis and lymphoinvasion in breast cancer[J].Cell Metab,2019,30(5):917-936.
11 Hu G,Zhong K,Chen W,et al.Podoplanin-positive cancer-associated fibroblasts predict poor prognosis in lung cancer patients[J].Onco Targets Ther,2018,11:5607-5619.
12 Qiao X,Sun Y,Zou Y,et al.Immunohistochemical staining of podoplanin is helpful in determining the microinvasion of cervical squamous cell carcinoma published online ahead of print[J].Ann Diagn Pathol,2020,46:151493.
13 Hsu YB,Huang CF,Lin KT,et al.Podoplanin,a potential therapeutic target for nasopharyngeal carcinoma[J].Biomed Res Int,2019,2019:7457013.
14 Eisemann T,Costa B,Harter PN,et al.Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma[J].Neuro Oncol,2019,21(3):326-336.
15 Wolber P,Schwarz D,Niemczyk M,et al.Expression of podoplanin correlates with prognosis in nasopharyngeal carcinoma[J].Eur Arch Otorhinolaryngol,2020,277(4):1185-1190.
16 Kato Y,Kaneko MK,Kunita A,et al.Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC2[J].Cancer Sci,2008,99(1):54-61.
17 Riedl J,Preusser M,Nazari PM,et al.Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism[J].Blood,2017,129(13):1831-1839.
18 Cioca A,Cimpean AM,Ceausu RA,et al.Evaluation of podoplanin expression in hepatocellular carcinoma using RNAscope and immunohistochemistry-a preliminary report[J].Cancer Genomics Proteomics,2017,14(5):383-387.
19 Krishnan H,Rayes J,Miyashita T,et al.Podoplanin:an emerging cancer biomarker and therapeutic target[J].Cancer Sci,2018,109(5):1292-1299.
20 Astarita JL,Acton SE,Turley SJ.Podoplanin:emerging functions in development,the immune system,and cancer[J].Front Immunol,2012,3:283.
21 Martín-Villar E,Borda-d'Agua B,Carrasco-Ramirez P,et al.Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability[J].Oncogene,2015,34(34):4531-4544.
22 Verma V,Chandrashekar C.Evaluation of SOX2 and podoplanin expression in oral epithelial dysplasia and its correlation with malignant transformation[J].J Investig Clin Dent,2019,10(4):e12450.
23 Shirai T,Inoue O,Tamura S,et al.C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice[J].J Thromb Haemost,2017,15(3):513-525.
24 Xu M,Wang X,Pan Y,et al.Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma[J].BMC Cancer,2019,19(1):599.
25 Bieniasz-Krzywiec P,Martín-Pérez R,Ehling M,et al.Podoplanin-expressing macrophages promote lymphangiogenesis and lymphoinvasion in breast cancer[J].Cell Metab,2019,30(5):917-936.
26 Neinaa YME,El-Ashmawy AA,Alshenawy HA,et al.The prognostic value of podoplanin expression in nonmelanoma skin cancers:correlation with lymphatic vessel density[J].Am J Dermatopathol,2020,42(6):432-438.
27 Xie L,Lin C,Zhang Q,et al.Elevated expression of podoplanin and its clinicopathological,prognostic,and therapeutic values in squamous non-small cell lung cancer[J].Cancer Manag Res,2018,10:1329-1340.
28 Königsbrügge O,Pabinger I,Ay C.Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study(CATS)[J].Thromb Res,2014,133(2):39-43.
29 Quintanilla M,Montero-Montero L,Renart J,et al.Podoplanin in inflammation and cancer[J].Int J Mol Sci,2019,20(3):707.
30 Payne H,Ponomaryov T,Watson SP,et al.Mice with a deficiency in CLEC2 are protected against deep vein thrombosis[J].Blood,2017,129(14):2013-2020.
31 Kunita A,Kashima TG,Morishita Y,et al.The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis[J].Am J Pathol,2007,170(4):1337-1347.
32 Lyman GH,Bohlke K,Khorana AA,et al.Venous thromboembolism prophylaxis and treatment in patients with cancer:american society of clinical oncology clinical practice guideline update 2014[J].J Clin Oncol,2015,33(6):654-656.
33 García Rodríguez LA,Martín-Pérez M,Hennekens CH,et al.Bleeding risk with long-term low-dose aspirin:a systematic review of observational studies[J].PLoS One,2016,11(8):e0160046.
34 Sekiguchi T,Takemoto A,Takagi S,et al.Targeting a novel domain in Podoplanin for inhibiting platelet-mediated tumor metastasis[J].Oncotarget,2016,7(4):3934-3946.
35 Kato Y,Kaneko MK,Kuno A,et al.Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain[J].Biochem Biophys Res Commun,2006,349(4):1301-1307.
36 Sekiguchi T,Takemoto A,Takagi S,et al.Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis[J].Oncotarget,2016,7(4):3934-3946.
37 Abe S,Kaneko MK,Tsuchihashi Y,et al.Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model[J].Cancer Sci,2016,107(9):1198-1205.
38 Nishinaga Y,Sato K,Yasui H,et al.Targeted phototherapy for malignant pleural mesothelioma:near-Infrared photoimmunotherapy targeting podoplanin[J].Cells,2020,9(4):1019.
39 Sudo H,Tsuji AB,Sugyo A,et al.Therapeutic efficacy evaluation of radioimmunotherapy with 90 Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma[J].Cancer Sci,2019,110(5):1653-1664.
40 Kato Y,Kaneko MK.A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin[J].Sci Rep,2014,4:5924.
41 Bender M,May F,Lorenz V,et al.Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice[J].Arterioscler Thromb Vasc Biol,2013,33(5):926-934.
42 Hughes CE,Navarro-Núñez L,Finney BA,et al.CLEC2 is not required for platelet aggregation at arteriolar shear[J].J Thromb Haemost,2010,8(10):2328-2332.
43 Tsukiji N,Osada M,Sasaki T,et al.Cobalt hematoporphyrin inhibits CLEC2-podoplanin interaction,tumor metastasis,and arterial/venous thrombosis in mice[J].Blood Adv,2018,2(17):2214-2225.
44 Sasaki T,Shirai T,Tsukiji N,et al.Functional characterization of recombinant snake venom rhodocytin:rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis[J].J Thromb Haemost,2018,16(5):960-972.

[1]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[2]	尹琦, 胡彦建, 崔普泽, 胡彦华. Notch信号通路调控肿瘤细胞凋亡机制研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 165-169.
[3]	秘嘉庆, 秦倩, 马惠涵, 马梅杰, 冯勤梅. TTK在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 188-192.
[4]	任思颖,秦明芳,陈杨,石青萍,成会荣,高娇,文洪梅. 云南省肿瘤登记地区2011—2015年宫颈癌发病和死亡特征及时间趋势[J]. 实用肿瘤学杂志, 2021, 35(1): 13-17.
[5]	刘学静(综述),徐燕颖(审校). B7-H6在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 46-49.
[6]	郑志远,综述,曲国蕃(审校). 长链非编码RNA SNHG3在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 50-54.
[7]	张文文,姜亮亮(综述),王晶(审校). CAR-T疗法在卵巢癌中的应用前景[J]. 实用肿瘤学杂志, 2021, 35(1): 59-63.
[8]	杨思琦,宋启斌,李清清(综述),姚颐(审校). 靶向抑制FGFRs信号在治疗恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 73-77.
[9]	王庆亮,赵艳峰,蒋燕(综述),姜格宁(审校). TPX2与肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 83-86.
[10]	冯羽昕(综述),朱春荣(审校). lncRNA-HEIH在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 87-90.
[11]	文洪梅, 陈杨, 石青萍, 任思颖, 高娇, 秦明芳. 2016年云南省肿瘤登记地区恶性肿瘤的发病和死亡分析[J]. 实用肿瘤学杂志, 2020, 34(6): 485-490.
[12]	相智声, 马晶昱, 钟文玲, 陈铁晖, 林永添, 江惠娟, 周衍. 福建省2016年恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2020, 34(6): 491-494.
[13]	孙晓凯, 刘付东, 梁季, 郑春早, 周金意. 江苏省盐城市2008—2018年消化道肿瘤死亡情况及其变化趋势分析[J]. 实用肿瘤学杂志, 2020, 34(6): 495-499.
[14]	李建昕, 沈彬杰, 王璇. 恶性肿瘤社区随访模式的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 540-543.
[15]	陈敏, 刘莉萍, 张玲. iTRAQ技术在消化道肿瘤研究中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(6): 549-553.